Spring Bank Pharmaceuticals Inc

Spring Bank Pharmaceuticals — F-star Therapeutics — Investor Presentation (November 2021)

29 slides from Spring Bank Pharmaceuticals's investor presentation, Nov 10, 2021

  1. Slide 1: Next Generation Immunotherapies. Overcoming Cancer.

    Q4 2021 Next Generation Immunotherapies. Overcoming Cancer. Exhibit 99.2

  2. Slide 2: Forward-looking statements

    Certain statements contained in this communication regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, known as the PSLRA. These

  3. Slide 3: Three Key Pillars for Success

    CONFIDENTIAL Three Key Pillars for Success Validated, patent protected bispecific antibody platform Platform Combining clinically proven targets Pathway Biomarker driven patient selection Patient

  4. Slide 4: F-star at a Glance

    Partnerships Developing next generation immunotherapies to transform the lives of patients with cancer Key Financial Highlights* NASDAQ: FSTX Headquarters: Cambridge, UK & Cambridge, US Common Shares Outstanding: 20.6M Cash: $71.0M Working on today’s ‘hot’ IO targets, LAG-3 & CD137 (4-1BB) *as of 30

  5. Slide 5: A Year of Delivery

    Progression of FS118 Phase 2 POC CPI resistant trial and CPI naïve trial Progression of FS120 & FS222 in Phase 1 trials Progression of SB 11285 in Phase 1 trial CONFIDENTIAL A Year of Delivery Pipeline: Significant Progress on Clinical Programs Bringing Potential New Treatment Options to Patients Cl

  6. Slide 6: Experienced Management Team

    Experienced Management Team Successful, experienced team with 20 approved drugs Three decades experience in the pharmaceutical and biotechnology industries Senior leadership roles in drug development Eliot Forster CEO, PhD MBA Medical oncologist with 25+ years' experience in clinical research in Eur

  7. Slide 7: Differentiated Bispecific Platform

    Unique Bispecific Structure Natural human antibody format with only 15-20 amino acid substitutions Easy to make and well tolerated to date 2 natural binding sites 2 new Fc antigen binding (Fcab) sites FcR null for improved safety potential Tetravalency Drives Differentiated MoA Crosslinking: Potent

  8. Slide 8: Advantages Over Other Approaches

    CONFIDENTIAL Advantages Over Other Approaches F-star mAb2 Traditional Antibody and Combinations Heterodimeric Bispecific Antibody Alternative Scaffold Bispecific Fragment Bispecific incl BITEs Tetravalent crosslinking Conditionality Potent, efficient clustering IgG-like structure 2 natural binding s

  9. Slide 9: Strong Intellectual Property Estate

    Patent portfolio leveraged for BD Licensed to Denali, Janssen & Merck KGaA Only company able to leverage the potency of Fc antigen binding Strong Intellectual Property Estate Pipeline Products FS118: Composition of matter until at least 2037 Dosing regimes and patient selection pending FS120: Compos

  10. Slide 10: Proprietary and Partnered Pipeline

    Proprietary and Partnered Pipeline CPI = Checkpoint Inhibitor Program Targets (Mechanism of action) Opportunity Preclinical Phase 1 Phase 2 Phase 3 FS118 LAG-3/PD-L1 (Dual inhibitor) Rescuing CPI treatment failures Improving outcomes in CPI naïve FS222 CD137/PD-L1 (Stimulator/inhibitor) Improving ou

  11. Slide 11: Four Differentiated Clinical Programs

    Four Differentiated Clinical Programs FS120 Improving CPI and chemotherapy outcomes CONDITIONAL OX40/CD137 (4-1BB) DUAL STIMULATOR FS118 Rescuing CPI-treatment failures & improving outcomes in CPI naïve LAG-3/PD-L1 DUAL INHIBITOR Tetravalent Bispecific mAb2 FS222 Improving outcomes in PD-L1 low tumo

  12. Slide 12: Near Term Expected Clinical Data Milestones

    Near Term Expected Clinical Data Milestones Financed for Multiple Clinical Milestones H2 2021 H1 2022 H2 2022 H2 2023 H1 2023 FS222 FS120 SB 11285 FS118 Business Development Additional Ph 1 data Ph 1a/b including Tecentriq combination update Update on dose escalation Safety, biomarker and prelimina

  13. Slide 13: FS118

    FS118 Rescuing CPI-treatment failures & improving outcomes in CPI naïve LAG-3 PD-L1

  14. Slide 14: FS118: Profound Immune Activation through LAG-3 Shedding

    FS118: Profound Immune Activation through LAG-3 Shedding LAG-3 PD-L1 T cell Human PBMC cell assay PD-L1+ Tumor cell PD-L1 driven LAG-3 shedding & removal of LAG-3 from cell surface FS118 Phase 1 data: Soluble LAG-3 in serum

  15. Slide 15: FS118 Clinical Strategy - Building Opportunity

    FS118 Clinical Strategy - Building Opportunity CPI = Checkpoint Inhibitor CPI resistant Rationale Benefits Value Superior to PD-1 alone CPI-naïve, PD-1 sensitive tumors Rescuing PD-1 treatment failures Acquired resistance Avoiding PD-1 resistance by preventing LAG-3 upregulation while inhibiting PD-

  16. Slide 16: FS118 Clinical Development Plan

    FS118 Clinical Development Plan Preliminary data Mid-2022 Ph I: First in Human Monotherapy dose escalation Complete n = 43 Heavily pre-treated all comers Confidence to launch Phase 2 proof of concept trial Safety, RP2D, Biomarkers Post PD-(L)1 Key Takeaways: Ph 2: PD-1 Resistant SCCHN (Biomarker enr

  17. Slide 17: FS222

    CD137 PD-L1 FS222 Improving outcomes in PD-L1 low tumors

  18. Slide 18: Tetravalent mAb2 Activity Superior to Combination/Monotherapy

    CONFIDENTIAL Tetravalent mAb2 Activity Superior to Combination/Monotherapy Tetravalent bispecific mAb2 observed to potently synergize PD-1/PD-L1 pathway inhibition with CD137 agonism Mouse MC38 Tumor Model 1mg/kg (approx. 12 mice/group) Activity also observed in CT26 model 100% Tumor-free

  19. Slide 19: FS222: Potent PD-L1 Driven CD137 Agonism

    FS222: Potent PD-L1 Driven CD137 Agonism CD137 PD-L1 FS222: High affinity to PD-L1 drives crosslinking. Low affinity (but high avidity) to CD137 avoids self-competition Competitors: High affinity to PD-L1 and CD137 promotes monospecific binding and less crosslinking and activation PD-L1+ Tumor cell

  20. Slide 20: FS222 Phase 1 Study Design

    FS222 Phase 1 Study Design: Seamless & Adaptive Updates late 2021 & H2 2022 PART A PART B PART C Cohort expansion Planned Dose escalation & PK/PD expansion Confidence to proceed to indication specific expansion n = 50+ On-going Safety, PK/PD, Biomarkers, Preliminary Efficacy n = 25+ Colorectal n = 2

  21. Slide 21: FS120

    OX40 CD137 FS120 Improving CPI and chemotherapy outcomes

  22. Slide 22: FS120: First in Class Dual Agonist

    FS120: First in Class Dual Agonist with Broad Potential For Combination Tumor cell Destabilizes Tregs Treg Improving anti-tumor immune response* by “Triple Activation” Activates CD8+ and NK effector cells Increases CD4+ cell helper activity Destabilizes Tregs T cell helper activity Cytotoxic T cell

  23. Slide 23: FS120 Phase 1 Study Design

    FS120: Phase 1 Study Design Safety and biomarker update H2 2022 PART A Initiate H2 2022 PART B PART C Determination of pharmacologically active dose Select FS120 dose in combination with pembrolizumab dose regimen​ Proof of concept​ Monotherapy dose escalation On-going PD-1 combo dosing frequency an

  24. Slide 24: STING agonist SB 11285

    STING agonist SB 11285 Improving CPI outcomes STING = Stimulator of Interferon Genes

  25. Slide 25: SB 11285 Elicits Robust Antitumor Activity Following IV Administration

    SB 11285 Elicits Robust Antitumor Activity Following IV Administration Tumor cell Bridging the gap between innate and adaptive immunity: Durable antitumor responses via activation of Antigen Presenting Cells (APCs) Cytotoxic T cells NK cells CD8+ T cell & NK cell Antigen presentation & Type I IFN se

  26. Slide 26: SB 11285 Phase 1 Study Design

    SB 11285 Phase 1 Study Design Key Takeaways: SB 11285 well tolerated alone and with atezolizumab across all dose levels to date Heavily pre-treated tumors with some early evidence of disease control PK profile aligns with expected immune cell uptake Biomarker data encourages further dose escalation

  27. Slide 27: FSTX – A Stellar Investment Opportunity

    CONFIDENTIAL FSTX – A Stellar Investment Opportunity © 2020 F-star. All rights reserved Validation of differentiated platform & pipeline with big pharma alliances Platform Four ongoing clinical programs with multiple data readouts in next 24 months Pipeline Broad patent portfolio protecting platform

  28. Slide 28: F-star Potential Next Generation Immunotherapies

    CONFIDENTIAL F-star Potential Next Generation Immunotherapies

  29. Slide 29: Thank you

    THERAPEUTICS Thank you.

F-star Therapeutics — Investor Presentation (November 2021) on 6ix